Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.98) per share which missed the analyst consensus estimate of $(0.83) by 18.07 percent. This is a 78.88 percent increase over losses of $(4.64) per share from the same period last year. The company reported quarterly sales of $9.01 million which missed the analyst consensus estimate of $10.01 million by 9.97 percent. This is a 1.30 percent increase over sales of $8.90 million the same period last year.